Aqualung Therapeutics Corp. Awarded $300K from NIH to Develop A Novel Therapeutic For Pregn

TUCSON, AZ/Accesswire/September 22, 2020/Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation in patients with serious acute and chronic diseases, has been awarded a one year  NIH FAST-TRACK AWARD  (1R41 HD101202-01A1) to support development of a humanized antibody therapy for pregnant women with intrauterine infection at risk for preterm birth. 

Each year over 400,000 preterm births occur annually in the US, the majority born to mothers with “chorioamnionitis” or intrauterine infection that occurs before or during labor. The name refers to the infection of the membranes surrounding the fetus: the “chorion” (outer membrane) and the “amnion” (fluid-filled sac) leading to a preterm birth and/or serious infection in the mother and the baby. Preterm births are at risk for a myriad of serious lung, gastroenterology, and cognitive complications as well as developmental delays.

Aqualung Therapeutics (ALT) scientists have identified extracellular NAMPT  or eNAMPT, a  master regulator of tissue and systemic inflammation as a novel therapeutic target in Chorioamnionitis. ALT has demonstrated robust NAMPT expression in placentas from women with chorioamnionitis. In a preclinical pregnant mouse model of ChorP, a eNAMPT-neutralizing antibody was dramatically protective, improving preterm birth mortality and inflammation in newborn pups.

This NIH STTR Award will drive the final selection of the lead eNAMPT-neutralizing humanized therapeutic mAb between two candidates, ALT-100 and ALT-200; with selection utilizing in vitro and preclinical in vivo models of chorioamnionitis.  Upon confirmation of the optimal mAb candidate in treating chorioamnionitis, Aqualung will submit an R42 STTR grant to further support pre-clinical development and IND-enabling studies. 

“This is the fourth NIH-supported indication for development of the eNAMPT platform along with ARDS, pulmonary hypertension and radiation lung injury. We are excited the NIH sees the value of our science and is willing to fund our early proof of concept development,” states Stan Miele President of Aqualung Therapeutics.

About Aqualung Therapeutics Corporation 

Aqualung is an early-stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Founded in 2016 and led by a physician scientist, Aqualung’s science-driven approaches led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases. Aqualung Therapeutics is developing eNamptor™, a Next Gen platform comprised of : i) ALT 100/200,  humanized eNAMPT-neutralizing monoclonal antibodies; ii) eNAMPT-Plex, a plasma-based biomarker panel comprised of cytokines, including eNAMPT, which predicts ARDS mortality; and iii) NAMPT-Gene, a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of ALT is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH). These conditions all exhibit a significant unmet medical need with significant morbidity and mortality. For additional information about the company, please visit www.aqualungtherapeutics.com.